Presentation is loading. Please wait.

Presentation is loading. Please wait.

Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and.

Published byAnnis Neal Modified over 5 years ago

Similar presentations

Presentation on theme: "Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and."— Presentation transcript:

1 Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials  Rogerio Lilenbaum, MD, Victoria M. Villaflor, MD, Corey Langer, MD, Kenneth O'Byrne, MD, Mary O'Brien, MD, Helen J. Ross, MD, Mark Socinski, MD, Fred B. Oldham, MD, Larissa Sandilac, MD, Jack W. Singer, MD, Philip Bonomi, MD  Journal of Thoracic Oncology  Volume 4, Issue 7, Pages (July 2009) DOI: /JTO.0b013e3181a9a020 Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 STELLAR 3 and 4 STUDY diagrams.
Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181a9a020) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Overall survival in days using Kaplan-Meier estimation (combination versus single-agent therapy). Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181a9a020) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Overall survival (in days) by risk. Factors using Kaplan-Meier estimation (All STELLAR 3 and 4 patients). Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181a9a020) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and."

Similar presentations

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304  Martin J. Edelman, MD, Lydia.

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB   Martin J. Edelman, MD, Lydia.
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients  Benjamin T. Gielda, MD,

Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients  Benjamin T. Gielda, MD,
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients  Benjamin T. Gielda, MD,

Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients  Benjamin T. Gielda, MD,
The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed,

The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed,
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base  Amy C. Moreno,

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base  Amy C. Moreno,
Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.
Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

Similar presentations

Ads by Google